Wildebeast
The true worth of VCR will be seen one day.When - who knows. What has happened to it, is IMO, an injustice to the company and its shareholders. Some of it may be self inflicted, that's history now.Moving forward, they need a bit more money, a relatively small percentage of what has been spent to date, to get them to a stage when they can be self funding. There will still be ongoing R and D costs, so there should be.When they receive FDA approval for BTT there will be a quick change to profitability. Once they, and they will, receive DT approval they will become massively profitable.Look at the figures, 82% of recipients alive and with a better quality of life after a year, and the promise of better to come.50000 odd people a year as candidates for a new heart. One other company Thoratec+ Heartware, as serious competitors.
Shareholders who funded the vast majority of this work over the past 6 or 8 years have every reason to want to hold their positions. They should be allowed to do so and IMO the management will have this firmly on the agenda when a deal is done.
What the company is worth now is hard to quantify, but Heartware were worth $420 odd million to Thoratec with a good product but a long way behind VCR and with unknown challenges ahead.
The real worth of the company will be seen in the future and as a long term SH I hope I am given the opportunity to share in the success of the product
- Forums
- ASX - By Stock
- so what is this co. worth now?
VCR
ventracor limited
WildebeastThe true worth of VCR will be seen one day.When - who...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online